Isturisa (osilodrostat) — Highmark
Cushing’s syndrome
Initial criteria
- age ≥ 18 years
- diagnosis of Cushing’s syndrome (ICD-10: E24)
- member is not a candidate for pituitary surgery OR pituitary surgery has not been curative
Reauthorization criteria
- member has experienced a reduction in the 24-hour mean urinary free cortisol (mUFC) levels from baseline
- prescriber attests that the member has experienced an improvement in signs and symptoms of Cushing’s syndrome from baseline
Approval duration
12 months